XORTX Announces $3 Mln Private Placement To Advance Gout And Kidney Disease Program
Neutral
0.0
(RTTNews) - XORTX Therapeutics Inc. (XRTX), a late-stage clinical pharmaceutical firm focused on therapies for progressive kidney disease and gout, has launched a non-brokered private placement to raise up to USD 3 million.
Pulse AI Analysis
Pulse analysis not available yet. Click "Get Pulse" above.
This analysis was generated using Pulse AI, Glideslope's proprietary AI engine designed to interpret market sentiment and economic signals. Results are for informational purposes only and do not constitute financial advice.
